Ghrelin was used as control with an EC50 of 0.9 nM (pEC50 = 9.05 ± 0.06, Emax = 100 ± 3%). Due to the partial agonism of the compounds, the effect of ghrelin cannot be completely antagonized. The assay provided IC50 values for (R)-9 and (S)-16 of 17.5 nM and 28.7 nM, respectively, which were similar to the antagonistic potency of the starting molecule (S)-9 of 24.8 nM. (S)-10, (S)-11, (S)-14, and (S)-13 were much less potent, as indicated by their IC50 values (Table S1 ). The highest antagonistic efficacy could be observed for (S)-16 (Emax of 65 %). Figure S1 . Antagonistic properties of the non-peptidic candidate compounds (S)-9, (R)-9, (S)-14, and (S)-16. Compounds were analyzed by inositol phosphate accumulation in COS7 cells stably transfected with hGhrR. Data were normalized to ghrelin (100% = maximal efficacy, 0% = constitutive receptor activity) and given in percent as means ± SEM of ≥ 3 independent experiments performed in duplicates. Table S2 . Results of (S)-9 screening by Eurofins Panlabs; for details on the methods see www.eurofinspanlabs.com.
